Market Chameleon (Thu, 18-Dec 4:37 AM ET)
Biodexa Pharmaceuticals Prices $10 Million U.S. Public Offering to Fund Pipeline
TipRanks (Thu, 18-Dec 8:57 AM ET)
Biodexa Pharmaceuticals prices $10M best-efforts public offering; shares down
Seeking Alpha News (Thu, 18-Dec 8:43 AM ET)
Biodexa Announces Pricing of $10 Million Public Offering
Globe Newswire (Thu, 18-Dec 8:30 AM ET)
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Benzinga (Tue, 16-Dec 5:53 AM ET)
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Globe Newswire (Mon, 1-Dec 8:30 AM ET)
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Globe Newswire (Mon, 24-Nov 8:30 AM ET)
Market Chameleon (Mon, 3-Nov 3:50 AM ET)
Globe Newswire (Mon, 3-Nov 8:30 AM ET)
Globe Newswire (Mon, 6-Oct 8:30 AM ET)
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Biodexa Pharmaceuticals PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol BDRX.
As of December 19, 2025, BDRX stock price declined to $3.70 with 282,266 million shares trading.
BDRX has a beta of 0.48, meaning it tends to be less sensitive to market movements. BDRX has a correlation of 0.01 to the broad based SPY ETF.
BDRX has a market cap of $2.29 million. This is considered a Sub-Micro Cap stock.
BDRX has underperformed the market in the last year with a price return of -90.6% while the SPY ETF gained +17.3%. BDRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.3% and -27.3%, respectively, while the SPY returned +3.3% and -0.6%, respectively.
BDRX support price is $3.47 and resistance is $4.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDRX shares will trade within this expected range on the day.